Orexo changes the organizational structure and management team to increase focus on development of new products
MWN-AI** Summary
Orexo AB, a Swedish pharmaceutical company, has announced significant changes to its organizational structure and management team aimed at intensifying its focus on the development of new products. This strategic realignment follows the divestment of Zubsolv® from the US market and underscores the company’s commitment to advancing its development programs alongside its proprietary AmorphOX® technology.
A pivotal appointment in the restructuring is Lisa Moore, who will take on the role of Senior Vice President, Products and Portfolio Strategy. With over 25 years of experience in the biopharma sector, Moore’s responsibilities will include shaping the long-term product vision and ensuring that Orexo’s portfolio aligns with customer needs. Her history as Vice President of Global Commercial Strategy at Emergent equips her to lead new product planning and strategy effectively. Moore’s enhanced role is symptomatic of Orexo’s shift towards prioritizing innovation and future product development.
Robert DeLuca, who has been President of Orexo US Inc. since its inception in 2013, will retire but remains integral to the transition with an advisory role, particularly to facilitate the handover of Zubsolv® to Dexcel Pharma USA. His contributions have been pivotal in building Orexo’s presence in the US market and advancing the fight against the opioid crisis.
Nikolaj Sorensen, CEO and President of Orexo, expressed gratitude toward DeLuca while emphasizing that the organizational changes aim to bolster Orexo’s pipeline and establish strategic partnerships moving forward. These developments reflect Orexo’s dedication to providing innovative treatments and adapting to the evolving healthcare landscape.
MWN-AI** Analysis
Orexo’s recent changes to its organizational structure and management team signal a strategic pivot aimed at enhancing its product development capabilities. This reorganization follows the divestment of Zubsolv® in the U.S. market and reflects the company’s commitment to advancing critical programs, particularly the innovative AmorphOX® technology.
Under Lisa Moore’s leadership as the new Senior Vice President of Products and Portfolio Strategy, Orexo is well-positioned to refine its product vision and ensure that its development pipeline aligns with market needs. Moore’s extensive experience in biopharma, including her prior role at Emergent, equips her with the strategic insight necessary to guide Orexo’s product offerings through a competitive landscape. This shift in focus towards new product development is crucial, particularly as healthcare continuously evolves, and addressing unmet medical needs can create significant market opportunities.
The retirement of Robert DeLuca marks the end of an era for Orexo, but his ongoing advisory role will aid in a smooth transition. DeLuca's strategic insights gained from years of experience will benefit the company as it seeks to establish strategic partnerships and advancements in its portfolio.
From an investor's perspective, these structural and leadership changes could enhance Orexo’s long-term valuation. An emphasis on R&D and product innovation is essential for sustained growth, especially in the pharmaceutical sector where pipeline advancements can drive revenues. As the company progresses with its revised strategy, it will be critical to monitor how quickly new products are developed and the potential impact on sales.
In conclusion, Orexo's recent organizational adjustments are a strategic move towards fostering innovation and reinforcing its market position. Investors should keep an eye on upcoming R&D results and strategic partnerships that will likely influence Orexo's performance moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team. The changes are a result of the divestment of Zubsolv® in the US market and focus on advancing development programs and the AmorphOX® technology.
Maintaining commercial and US market competence is important to ensure new products are developed to address unmet customer needs. Lisa Moore, who has been part of Orexo's US leadership team since May 2024, will assume a new responsibility as Senior Vice President, Products and Portfolio Strategy. In her new role, she will be responsible for driving the long-term product vision for the development candidates, ensuring that the portfolio meets customer needs and that investment decisions support business growth.
Lisa Moore is a biopharma industry leader with more than 25 years of experience in commercial, new product planning, and strategy roles. Prior to joining Orexo in 2024, she was Vice President, Global Commercial Strategy at Emergent, where she also led the commercial valuation of M&A opportunities. She has previously held management positions at MedImmune, Parke-Davis, Baxter International, and Merck. Lisa Moore will be a part of Orexo´s management team and report directly to the CEO. She will participate in Orexo's R&D Day on March 24 in Stockholm.
Robert DeLuca, President of Orexo US Inc. since the launch of the US commercial organization in 2013, has been instrumental in building the US business, leading the successful commercialization of Zubsolv and advancing Orexo's mission to help curb the US opioid epidemic. Robert DeLuca will retire from his role at the company.
Nikolaj Sorensen, CEO & President of Orexo, said: "As Orexo enters a new chapter, we are aligning our organization to best support our long-term priorities and value creation ambitions. These changes sharpen our focus on advancing our pipeline, unlocking the potential of AmorphOX, and building strong strategic partnerships. As we enter this next phase, I also want to express my sincere gratitude to Bob DeLuca. Over more than a decade, Bob has been a close business partner and an outstanding leader, playing a pivotal role in building our US business and bringing Zubsolv to patients. His commitment, integrity, and impact on Orexo will be lasting, and I am personally thankful for our many years of close collaboration."
Robert DeLuca will continue in his role as President of Orexo US Inc. through May 2026. He will also, after May continue to support the company with strategic projects and with the transition of Zubsolv® US to Dexcel Pharma USA in an advisory role.
For further information contact:
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm's main market and trades as ADRs on the OTCQX market in the United States.
For more information, please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
The information was submitted for publication at 3.30 pm CET on March 6, 2026.
CONTACT:
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://news.cision.com/orexo/i/orexo-lisa-moore-svp-product-and-portfolio-strategy-,c3517346 | orexo-lisa-moore SVP Product and Portfolio Strategy |
SOURCE Orexo
FAQ**
How will the changes to Orexo AB ORXOF's management team support the advancement of development programs and the AmorphOX® technology?
What specific strategies does Lisa Moore plan to implement in her new role to ensure that Orexo AB ORXOF's product portfolio addresses customer needs effectively?
What opportunities does Orexo AB ORXOF see in the transition of Zubsolv® and how will this affect its overall product development strategy?
How will Orexo AB ORXOF maintain its commercial competence in the US market following Robert DeLuca's retirement from his role?
**MWN-AI FAQ is based on asking OpenAI questions about Orexo AB ADR (OTC: ORXOY).
NASDAQ: ORXOY
ORXOY Trading
237.22% G/L:
$2.60 Last:
100 Volume:
$2.60 Open:
